$SILK
Silk Road Medical Inc Stock $silk

$silk Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-Q Financial Statement

#000139770219000028 Filed on November 13, 2019

Income Statement

Concept	2019 Q4	2019 Q3	2018 Q3
Revenue	$18.63M	$17.03M	$9.614M
YoY Change	62.46%	77.1%
Cost Of Revenue	$4.720M	$4.170M	$2.882M
YoY Change	28.61%	44.69%
Gross Profit	$13.91M	$12.86M	$6.732M
YoY Change	78.3%	90.97%
Gross Profit Margin	74.66%	75.51%	70.02%
Selling, General & Admin	$18.16M	$17.06M	$8.973M
YoY Change	55.08%	90.17%
% of Gross Profit	130.53%	132.73%	133.29%
Research & Development	$3.260M	$3.187M	$2.442M
YoY Change	-3.83%	30.51%
% of Gross Profit	23.43%	24.79%	36.27%
Depreciation & Amortization	$180.0K	$180.0K	$200.0K
YoY Change	-5.26%	-10.0%
% of Gross Profit	1.29%	1.4%	2.97%
Operating Expenses	$21.42M	$20.25M	$11.42M
YoY Change	41.85%	77.41%
Operating Profit	-$7.507M	-$7.395M	-$4.683M
YoY Change	2.88%	57.91%
Interest Expense	-$780.0K	$1.176M	$1.065M
YoY Change	-33.33%	10.42%
% of Operating Profit
Other Income/Expense, Net	-$10.00K	-$1.000K	-$3.233M
YoY Change	-99.86%	-99.97%
Pretax Income	-$8.290M	-$8.010M	-$8.950M
YoY Change	-46.93%	-10.5%
Income Tax
% Of Pretax Income
Net Earnings	-$8.291M	-$8.007M	-$8.952M
YoY Change	-46.91%	-10.56%
Net Earnings / Revenue	-44.49%	-47.03%	-93.11%
Basic Earnings Per Share
Diluted Earnings Per Share	-$266.7K	-$260.4K	-$296.1K
COMMON SHARES
Basic Shares Outstanding	30.87M shares	30.76M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2019 Q3	2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$108.9M	$112.3M
YoY Change
Cash & Equivalents	$39.18M	$112.3M	$31.02M
Short-Term Investments	$69.73M
Other Short-Term Assets	$2.900M	$3.500M
YoY Change
Inventory	$10.32M	$9.275M
Prepaid Expenses
Receivables	$8.601M	$6.932M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$112.5M	$132.0M
YoY Change	192.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.734M	$2.697M
YoY Change	-5.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$18.20M
YoY Change
Other Assets	$3.644M	$3.575M
YoY Change	254.13%
Total Long-Term Assets	$24.91M	$6.582M
YoY Change	490.47%
TOTAL ASSETS
Total Short-Term Assets	$112.5M	$132.0M
Total Long-Term Assets	$24.91M	$6.582M
Total Assets	$137.4M	$138.6M
YoY Change	221.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.898M	$1.965M
YoY Change	51.6%
Accrued Expenses	$15.03M	$10.48M
YoY Change	59.12%
Deferred Revenue	$304.0K	$335.0K
YoY Change	121.9%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$16.93M	$12.44M
YoY Change	58.24%
LONG-TERM LIABILITIES
Long-Term Debt	$44.88M	$44.79M
YoY Change	1.53%
Other Long-Term Liabilities	$3.700M	$3.900M
YoY Change	246.12%
Total Long-Term Liabilities	$48.58M	$48.69M
YoY Change	7.31%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.93M	$12.44M
Total Long-Term Liabilities	$48.58M	$48.69M
Total Liabilities	$65.51M	$61.13M
YoY Change	-9.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$191.5M	-$183.2M
YoY Change	37.68%
Common Stock	$31.00K	$31.00K
YoY Change	3000.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$71.89M	$77.44M	-$119.2M
YoY Change
Total Liabilities & Shareholders Equity	$137.4M	$138.6M
YoY Change	221.46%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2018 Q3
OPERATING ACTIVITIES
Net Income	-$8.291M	-$8.007M	-$8.952M
YoY Change	-46.91%	-10.56%
Depreciation, Depletion And Amortization	$180.0K	$180.0K	$200.0K
YoY Change	-5.26%	-10.0%
Cash From Operating Activities	-$5.260M	-$6.350M	-$6.370M
YoY Change	-2.41%	-0.31%
INVESTING ACTIVITIES
Capital Expenditures	-$200.0K	-$130.0K	-$1.170M
YoY Change	81.82%	-88.89%
Acquisitions
YoY Change
Other Investing Activities	-$69.42M
YoY Change	-694300.0%
Cash From Investing Activities	-$69.62M	-$130.0K	-$1.170M
YoY Change	69520.0%	-88.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.790M	500.0K	15.22M
YoY Change	-878.26%	-96.71%
NET CHANGE
Cash From Operating Activities	-5.260M	-6.350M	-6.370M
Cash From Investing Activities	-69.62M	-130.0K	-1.170M
Cash From Financing Activities	1.790M	500.0K	15.22M
Net Change In Cash	-73.09M	-5.980M	7.680M
YoY Change	1177.8%	-177.86%
FREE CASH FLOW
Cash From Operating Activities	-$5.260M	-$6.350M	-$6.370M
Capital Expenditures	-$200.0K	-$130.0K	-$1.170M
Free Cash Flow	-$5.060M	-$6.220M	-$5.200M
YoY Change	-4.17%	19.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001397702
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.3704
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2019-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38847
	dei	Entity Registrant Name EntityRegistrantName	SILK ROAD MEDICAL, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8777622
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1213 Innsbruck Dr.
	dei	Entity Address City Or Town EntityAddressCityOrTown	Sunnyvale
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94089
	dei	City Area Code CityAreaCode	408
	dei	Local Phone Number LocalPhoneNumber	720-9002
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	SILK
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2019Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30865553	shares
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	112277000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24990000	USD
CY2019Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6932000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4520000	USD
CY2019Q3	us-gaap	Inventory Net InventoryNet	9275000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	5744000	USD
CY2019Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3503000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1408000	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	131987000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	36662000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2697000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2880000	USD
CY2019Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	310000	USD
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1965000	USD
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	310000	USD
CY2019Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3575000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1029000	USD
CY2019Q3	us-gaap	Assets Assets	138569000	USD
CY2018Q4	us-gaap	Assets Assets	40881000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1252000	USD
CY2019Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10476000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7586000	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	12441000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8838000	USD
CY2019Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	44785000	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	44201000	USD
CY2019Q3	silk	Preferred Stock Warrant Liability PreferredStockWarrantLiability	0	USD
CY2018Q4	silk	Preferred Stock Warrant Liability PreferredStockWarrantLiability	16091000	USD
CY2019Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3900000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1069000	USD
CY2019Q3	us-gaap	Liabilities Liabilities	61126000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	70199000	USD
CY2019Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0	shares
CY2018Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	24069615	shares
CY2019Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2019Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2018Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	21233190	shares
CY2018Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	21233190	shares
CY2019Q3	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	0	USD
CY2018Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	121144000	USD
CY2019Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2018Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	105235000	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	29879220	shares
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30775980	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30775980	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1135310	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1135310	shares
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	31000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2019Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	260647000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4557000	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-183235000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-139111000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	77443000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-134553000	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	138569000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40881000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17026000	USD
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2882000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23087000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4170000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	11206000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7207000	USD
CY2019Q3	us-gaap	Gross Profit GrossProfit	12856000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9614000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44721000	USD
CY2018Q3	us-gaap	Gross Profit GrossProfit	6732000	USD
	us-gaap	Gross Profit GrossProfit	33515000	USD
	us-gaap	Gross Profit GrossProfit	15880000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3187000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2442000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9008000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6868000	USD
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17064000	USD
CY2018Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8973000	USD
	us-gaap	Operating Expenses OperatingExpenses	54072000	USD
	us-gaap	Operating Expenses OperatingExpenses	29976000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	45064000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	23108000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	20251000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	11415000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7395000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4683000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20557000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14096000	USD
CY2019Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	565000	USD
CY2018Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	28000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1215000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	65000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	1176000	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	1065000	USD
	us-gaap	Interest Expense InterestExpense	3736000	USD
	us-gaap	Interest Expense InterestExpense	3065000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3233000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-21046000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4915000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-8007000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	-8007000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-8953000	USD
CY2018Q3	us-gaap	Profit Loss ProfitLoss	-8953000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-44124000	USD
	us-gaap	Profit Loss ProfitLoss	-44124000	USD
	us-gaap	Profit Loss ProfitLoss	-22011000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-22011000	USD
CY2019Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	USD
CY2018Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-1000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-1000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-8007000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8007000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-8952000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8952000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-44124000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44124000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22010000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22010000	USD
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-8.49
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.18
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-24.14
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30764354	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1054794	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20249580	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	911873	shares
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-134553000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	375000	USD
CY2019Q1	silk	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	0	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	241000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	21000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-24158000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-24158000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	-158074000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	364000	USD
CY2019Q2	silk	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	31000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	144140000	USD
CY2019Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2561000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	-119169000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	109039000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	814000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	22000	USD
CY2019Q2	us-gaap	Profit Loss ProfitLoss	-11959000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-11959000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	84377000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	68000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	80000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	902000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	23000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	-8007000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-8007000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	77443000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-98578000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	284000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	164000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	-2000	USD
CY2018Q1	us-gaap	Profit Loss ProfitLoss	-5408000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-5408000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	-103453000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	148000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	178000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	151000	USD
CY2018Q2	us-gaap	Profit Loss ProfitLoss	-7651000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-7651000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	-110627000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	216000	USD
CY2018Q3	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	1000	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	179000	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	15000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-8953000	USD
CY2018Q3	us-gaap	Profit Loss ProfitLoss	-8953000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1515000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3609000	USD
	us-gaap	Profit Loss ProfitLoss	-44124000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	15000000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	21030000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4907000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	1153000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1163000	USD
	us-gaap	Profit Loss ProfitLoss	-22011000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	530000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	325000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2023000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	685000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	34000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	57000	USD
	silk	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	440000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	595000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1255000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	78000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3575000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1925000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2096000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	437000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-764000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	58000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	712000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-565000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2255000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1379000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-569000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	445000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24349000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16305000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	337000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2168000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-337000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2168000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	109352000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	806000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	649000	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	1000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	111973000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15650000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	87287000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2823000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25300000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33841000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	112587000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31018000	USD
	us-gaap	Interest Paid Net InterestPaidNet	3107000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1855000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9000	USD
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30764354	shares
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	26000	USD
	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	0	USD
	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	794000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3982000	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	37121000	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	144140000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to the common stock valuation and related stock-based compensation, the valuation of the redeemable convertible preferred stock warrants, the valuation of deferred tax assets, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and the reserves for sales returns. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div>
CY2019Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	721000	USD
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	310000	USD
CY2019Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	310000	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Concentration of Credit Risk, and Other Risks and Uncertainties</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable to the extent of the amounts recorded on the condensed consolidated balance sheet.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company’s policy is to invest in money market funds, which are classified as cash equivalents on the condensed consolidated balance sheet. The Company's cash is held in Company accounts at two financial institutions and such amounts may exceed federally insured limits. The Company's money market funds are invested in highly rated money market funds. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company provides for uncollectible amounts when specific credit problems are identified. In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for doubtful accounts.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company’s accounts receivable are due from a variety of health care organizations in the United States. At September 30, 2019 and December 31, 2018, no customer represented 10% or more of the Company’s accounts receivable. For the three and nine months ended September 30, 2019 and September 30, 2018, there were no customers that represented 10% or more of revenue. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company manufactures certain of its commercial products in-house. Certain of the Company’s product components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE stent. Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company’s financial position and results of operations.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be no assurance that the Company’s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Existing or future devices developed by the Company may require approvals or clearances from the FDA or international regulatory agencies. In addition, in order to continue the Company’s operations, compliance with various federal and state laws is required. If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company’s currently approved portfolio. If clearance for the products in the current portfolio were withdrawn by the FDA, this would have a material adverse impact on the Company.</span></div>
CY2019Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	USD
CY2018Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	950000	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3982000	USD
CY2019Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4469000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	144140000	USD
CY2019Q3	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	149000	USD
CY2018Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	128000	USD
CY2019Q3	us-gaap	Inventory Net InventoryNet	9275000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-8007000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-8952000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-44124000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22010000	USD
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1054794	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20249580	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	911873	shares
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-8.49
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.18
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-24.14
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4677878	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28205275	shares
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4690000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2018Q4	us-gaap	Inventory Net InventoryNet	5744000	USD
CY2018Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	0	USD
CY2019Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	0	USD
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	16091000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-21030000	USD
	silk	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassifications FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifications	37121000	USD
CY2019Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	USD
CY2019Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1029000	USD
CY2018Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1054000	USD
CY2019Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	8246000	USD
CY2019Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6984000	USD
CY2018Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	5157000	USD
CY2019Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	841000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1014000	USD
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	749000	USD
CY2019Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	423000	USD
CY2018Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	313000	USD
CY2019Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	335000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	137000	USD
CY2019Q3	silk	Accrued Travel Expenses Current AccruedTravelExpensesCurrent	394000	USD
CY2018Q4	silk	Accrued Travel Expenses Current AccruedTravelExpensesCurrent	270000	USD
CY2019Q3	silk	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	197000	USD
CY2018Q4	silk	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	244000	USD
CY2019Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	553000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	451000	USD
CY2019Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10476000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7586000	USD
CY2018Q3	silk	Debt Maximum Borrowing Capacity DebtMaximumBorrowingCapacity	15000000	USD
	silk	Debt Instrument Covenant Maximum Liquidity Amount DebtInstrumentCovenantMaximumLiquidityAmount	3000000	USD
CY2016	silk	Debt Instrument Covenant Minimum Net Revenue Amount DebtInstrumentCovenantMinimumNetRevenueAmount	1000000	USD
CY2017	silk	Debt Instrument Covenant Minimum Net Revenue Amount DebtInstrumentCovenantMinimumNetRevenueAmount	5000000	USD
CY2018	silk	Debt Instrument Covenant Minimum Net Revenue Amount DebtInstrumentCovenantMinimumNetRevenueAmount	15000000	USD
	silk	Debt Instrument Liquidity Covenant Term DebtInstrumentLiquidityCovenantTerm	P90D
CY2019Q3	us-gaap	Long Term Debt LongTermDebt	44785000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	904000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5485000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	835000	USD
CY2019Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	48256000	USD
CY2019Q3	silk	Long Term Debt Gross Before Accretion Of Closing Fees LongTermDebtGrossBeforeAccretionOfClosingFees	58272000	USD
CY2019Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	1120000	USD
CY2019Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	4454000	USD
CY2019Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	4442000	USD
CY2019Q3	silk	Long Term Debt Accretion Of Closing Fees LongTermDebtAccretionOfClosingFees	1122000	USD
CY2019Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	59394000	USD
CY2019Q3	silk	Long Term Debt Unpaid Interest LongTermDebtUnpaidInterest	14458000	USD
CY2019Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	151000	USD
CY2019Q3	us-gaap	Long Term Debt LongTermDebt	44785000	USD
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	217000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	652000000	USD
CY2019Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	178000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	1002000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1002000	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	4650000	USD
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	749000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	540000000	USD
CY2019Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0650
CY2019Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y29D
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3543000	USD
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3901000	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	4650000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	255000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1037000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1066000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1096000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1127000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1031000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1044000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1920000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	5999000	USD
CY2019Q3	us-gaap	Purchase Obligation PurchaseObligation	3715000	USD
CY2018Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	24069615	shares
CY2018Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	21233190	shares
CY2018Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	21233190	shares
CY2018Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	121144000	USD
CY2018Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	105235000	USD
CY2019Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30775980	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30775980	shares
	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
	silk	Common Stock Vote Per Share CommonStockVotePerShare	1	vote
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	57889	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4364377	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.79
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M9D
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	33132000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	2317000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	792673	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	792673	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	21.82
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	456147	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.77
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	23025	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	23025	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	6.73
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1605241	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4677878	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.03
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M7D
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	120092000	USD
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2701774	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.53
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y3M
CY2019Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	78404000	USD
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4677878	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.03
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y3M7D
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	120092000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	10846000	USD
CY2019Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	8493000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y1M28D
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	925000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	194000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2023000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	685000	USD

Files In Submission

Name	View Source	Status
0001397702-19-000028-index-headers.html	Edgar Link	pending
0001397702-19-000028-index.html	Edgar Link	pending
0001397702-19-000028.txt	Edgar Link	pending
0001397702-19-000028-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
q32019exhibit311.htm	Edgar Link	pending
q32019exhibit312.htm	Edgar Link	pending
q32019exhibit321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
silk-20190930.htm	Edgar Link	pending
silk-20190930.xsd	Edgar Link	pending
silk-20190930_cal.xml	Edgar Link	unprocessable
silk-20190930_def.xml	Edgar Link	unprocessable
silk-20190930_htm.xml	Edgar Link	completed
silk-20190930_lab.xml	Edgar Link	unprocessable
silk-20190930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SILK
Silk Road Medical Inc Stock $silk

2019 Q4 Form 10-Q Financial Statement

#000139770219000028 Filed on November 13, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SILK Silk Road Medical Inc Stock $silk

2019 Q4 Form 10-Q Financial Statement

#000139770219000028 Filed on November 13, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SILK
Silk Road Medical Inc Stock $silk